Originator: La Jolla Pharmaceutical Company

First marketed by: La Jolla Pharmaceutical Company, subsidiary of Innoviva Inc.

Name of FDF: Giapreza®

Original FDF: RTU solution to be diluted for continuous intravenous infusion

Mode of Action
Synthetic form of angiotensin II, a naturally occurring peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure. Angiotensin type 1 receptor agonists

Indications
Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock

Patent status
Intravenous infusion formulation is still patented until 2027-12-21